2023 World Conference on Lung Cancer (Posters)-EP12.01. Real-word Study of Aumolertinib Treatment for Advanced NSCLC Patients with Uncommon EGFR Mutations in Late Permian Coal Area

EP12.01. Real-word Study of Aumolertinib Treatment for Advanced NSCLC Patients with Uncommon EGFR Mutations in Late Permian Coal Area - PDF(Abstract)

Back to course

Pdf Summary

This abstract describes a real-world study focusing on the treatment of advanced non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations in the Late Permian coal-accumulating areas of Yunnan and Guizhou Provinces in China. The study aims to evaluate the efficacy and safety of aumolertinib, a third-generation EGFR-TKI, as a first-line treatment option for these patients.<br /><br />The research is being conducted as a single arm, prospective, multicenter, real-world clinical trial. Eligible patients must be 18 years or older with locally advanced or metastatic NSCLC and harbor uncommon mutations specific to the coal-accumulating areas. Aumolertinib is administered orally at a dose of 110mg once daily for a treatment cycle of 21 days or until disease progression or intolerable toxicity occurs.<br /><br />The primary endpoint of the study is the objective response rate (ORR) assessed by the investigators using RECIST v1.1 criteria. Secondary endpoints include disease control rate (DCR), progression-free survival (PFS), overall survival (OS), safety, and laboratory abnormalities. Tumor tissue and peripheral blood samples will be collected at various time points for exploratory analysis, including baseline, first to fourth assessments (peripheral blood only), and disease progression.<br /><br />The unique incidence mode of uncommon EGFR mutations in these coal-accumulating areas is believed to be related to carcinogens in C1 coal burning. Patients in these regions have a high unmet need for treatment options for their specific mutations. Aumolertinib has shown efficacy in tumors with sensitive EGFR mutations and the T790M resistance mutation. This study aims to address this unmet need and provide an opportunity for improved cure rates.<br /><br />This study is the first prospective real-world investigation into the use of aumolertinib as a first-line treatment for patients with uncommon EGFR mutations in the coal-accumulating areas. Recruitment for the trial is ongoing.

Asset Subtitle

Jia gang Feng

Meta Tag

Speaker Jia gang Feng

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

advanced non-small cell lung cancer

NSCLC

uncommon EGFR mutations

Late Permian coal-accumulating areas

Yunnan

Guizhou Provinces

China

aumolertinib

first-line treatment

prospective clinical trial